New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...
The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...
With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...
Term Maintenance and Durability THOUSAND OAKS, Calif., and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (Kyowa ...
Amgen has reported positive phase 3 results with its biosimilar version of AstraZeneca/Alexion's blockbuster rare disease drug Soliris, setting up a regulatory filing with the FDA.
The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging advanced biopharmaceuti ...
We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results